Skip to main content
David Sallman, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

DavidASallmanMD

Oncology • Tampa, FL

Hematologic Oncology

Assistant Member, Malignant Hematology Department, Moffitt Cancer Center

Request Appointment

Overview of Dr. Sallman

Dr. David Sallman is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of South Florida Morsani College of Medicine and has been in practice 7 years. He is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • University of South Florida Morsani
    University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2013 - 2016
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2010 - 2013
  • University of South Florida College of Medicine
    University of South Florida College of MedicineClass of 2010

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2013 - 2025
  • MA State Medical License
    MA State Medical License 2012 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Junior Faculty Research Award for Clinical Science 2020
  • Best Abstract Award Winner Moffitt Research Symposium 2016
  • Alpine Oncology Foundation Young Investigator 2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts
    David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
    David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
    David A Sallman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results. 
    2019 ASCO Annual Meeting - 6/1/2019
  • TP53 Mutations Predict Poorer Responses to CPX-351 in Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Magrolimab plus Azacitidine Results in Promising Activity in Higher-Risk MDS Patients
    Magrolimab plus Azacitidine Results in Promising Activity in Higher-Risk MDS PatientsMarch 9th, 2023
  • First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
    First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic SyndromesDecember 9th, 2022
  • Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS
    Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDSSeptember 29th, 2022
  • Join now to see all

Hospital Affiliations

Dr. David Sallman, Dr. David Sallman, MD, Dr. D Sallman, Dr. David A Sallman